Physician profile
Michael D Barron
NPI 1508837014
$6,516.50
in general payments reported to CMS, 2019-2025
29 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $581 · 2021: $531 · 2022: $1,223 · 2023: $1,073 · 2024: $1,145 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,346.76 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Pfizer INC. | $725.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $691.72 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $587.93 | 2019-2024 | Xarelto |
| Amgen INC. | $519.97 | 2020-2025 | Repatha, Repatha |
| Novo Nordisk INC | $382.71 | 2023-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $336.27 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.03 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $302.11 | 2019-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $194.66 | 2019-2025 | Eliquis, Camzyos |
| Akcea Therapeutics, INC. | $155.62 | 2019 | |
| Amarin Pharma, INC. | $148.42 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $140.58 | 2019-2023 | |
| Scpharmaceuticals INC. | $112.81 | 2023-2025 | |
| Astellas Pharma US INC | $104.00 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.09 | 2021-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $57.99 | 2021-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $51.48 | 2024 | Arcalyst |
| Dentsply Sirona INC | $49.11 | 2022 | |
| Esperion Therapeutics, INC. | $45.33 | 2023-2024 | Nexletol |
| Medtronic, INC. | $44.45 | 2024 | Micra |
| Lexicon Pharmaceuticals, INC. | $32.01 | 2024 | |
| Impulse Dynamics (USA) INC. | $28.46 | 2022 | |
| Abbott Laboratories | $19.50 | 2024 | Mitraclip |
| Gilead Sciences, INC. | $17.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.57 | 2019 | |
| Kestra Medical Technology Services, INC. | $13.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.